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The creation of red blood cells for the blood transfusion markets represents a highly innovative
application of regenerative medicine with a medium term (5–10 year) prospect for first clinical studies.
This article describes a case study analysis of a project to derive red blood cells from human embryonic
stem cells, including the systemic challenges arising from (i) the selection of appropriate and viable
regulatory protocols and (ii) technological constraints related to stem cell manufacture and scale up to
clinical Good Manufacturing Practice (GMP) standard.
The method used for case study analysis (Analysis of Life Science Innovation Systems (ALSIS)) is also
innovative, demonstrating a new approach to social and natural science collaboration to foresight
product development pathways. Issues arising along the development pathway include cell
manufacture and scale-up challenges, affected by regulatory demands emerging from the innovation
ecosystem (preclinical testing and clinical trials). Our discussion reflects on the efforts being made by
regulators to adapt the current pharmaceuticals-based regulatory model to an allogeneic regenerative
medicine product and the broader lessons from this case study for successful innovation and
translation of regenerative medicine therapies, including the role of methodological and regulatory
innovation in future development in the field.Introduction: background to the case study
Regenerative medicine (RM) is a highly promising area for the
development of novel therapies with the capacity to solve intrac-
table human health problems. Applications range from one-off
autologous therapies where a patient’s own cells are extracted and
cultured before being transplanted back into the same patient, to
allogeneic therapies requiring large scale culturing of cells from a
single donor that are then provided to many patients. Autologous
therapies, akin to the ‘surgical procedure’ model (low volume/high
cost), are currently delivering successful treatments in several
areas. Allogeneic therapies, the subject of this paper, are muchCorresponding author: Mittra, J. (James.Mittra@ed.ac.uk)
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180 1871-6784/ 2014 The Authors. Published by Elsevier B.more challenging [1]. They are being developed for widespread
distribution to large numbers of patients and will be cultured in
large scale production facilities, requiring levels of scale-up that are
currently very difficult to achieve. However, successful develop-
ment of allogeneic therapies will be needed if regenerative medi-
cine is to fulfil its promise to meet future healthcare needs on a
significant scale. Such products are analogous to a pharmaceutical
production model (high volume/widely distributed product for
large patient populations) with its expected economies of scale.
The Bloodpharma case study described in this paper is an
important test case for the future development of allogeneic
therapies. It involves the industrial scale production of cultured
red blood cells (RBCs) from pluripotent stem cell lines and aimshttp://dx.doi.org/10.1016/j.nbt.2014.07.008
V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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arising from problems in the current supply chain, risks of trans-
fusion transmitted infection and risks associated with immune
responses for patients requiring repeat transfusions. It illustrates
many of the uncertainties faced by allogeneic RM therapies:
identifying and developing viable product development pathways
and funding models [2–4]; related scientific, technological and
regulatory challenges [5] and bio-processing/scale up options [6,7];
difficulties in implementing the regulatory system based on the
pharmaceutical model adopted for RM products [8–11]; and reim-
bursement and clinical uptake [12].
Socio-economic research on RM-related issues has so far been
done from a range of mono-disciplinary or narrowly focused
perspectives. These include the development, standardisation
and regulation of early stage stem cell research [13,14]; the storage
and handling of new types of biological material [15]; ethical
traditions and international differences in the approval of stem
cell research [16,17]; the politics of stem cell research and public
engagement [18,19]; socio-economic expectations of stem cell
treatment [20,21]; the known and potential risks of cell therapies
and the implications of proposed regulations for late stage inno-
vation [22–25]; and the manufacturing, scale up, and supply
challenges in delivering RM as a commercially viable technology
[6,7,26,27].
This paper describes the first major application of a novel
interdisciplinary approach to life science innovation (Analysis
of Life Science Innovation Systems (ALSIS)) [2], adopting a strate-
gic mapping approach to the projection of development pathways
for cultured red blood cells, and demonstrating how social and
natural science collaboration can deliver important new insights
on life science innovation processes. This interdisciplinary and
systemic approach allows consideration of interactions across the
science/innovation/policy/regulatory nexus to deliver insights
that would not otherwise emerge from a conventional socio-
economic analysis and to support better decision making by both
innovators and policy makers. By linking the regulatory pathway
with the manufacturing/scale-up pathway for this product, and
illustrating where the two must successfully align, this article is the
first systemic foresight analysis of a novel product in early stage
development and provides data that are relevant to, and can
inform, broader debates about the development of regenerative
medicine products.
Our analysis focuses on challenges to the development of the
Bloodpharma product arising from: scientific and technical uncer-
tainties; the regulatory system; manufacturing/scale up chal-
lenges; and the impact of all these factors on potential markets
and the overall commercial viability of the product.
Research method and data sources
The Blood Pharma Case Study – target market for the product
The Bloodpharma project is a strategic partnership funded by the
Wellcome Trust and the Scottish Funding Council to deliver a stem
cell-derived blood product (http://www.wellcome.ac.uk/news/
media-office/Press-releases/2009/WTX054309.htm). This was
one of three case studies considered for the REALISE project [2],
funded by the UK Economic and Social Research Council (ESRC)
through the Technology Strategy Board. The authors of this
paper (Innogen and Bloodpharma Project researchers) workedtogether to map the future product development pathway envis-
aged for the Bloodpharma therapy. This project, and our analysis,
were completed in 2012 and do not cover subsequent develop-
ments that are resolving some of the important uncertainties
described here.
Global demand for blood for routine transfusion is approxi-
mately 100 million units/year, each requiring 2.5  10e12 RBCs.
Previous attempts to develop ‘artificial’ blood have failed due to
problems with toxicity and manufacture [28,29] but stem cell
science offers the potential successfully to differentiate RBCs for
clinical use. However, achieving this scale of production to clinical
grade GMP standard at a price that is competitive with that of a
standard unit of blood is currently a challenging aim. The Blood-
pharma project has focused initially on the beta-Thalassemia
market where patients suffer problems with iron loading, for
which drugs with unpleasant side effects must be administered
[30,31]. The cultured RBCs could reduce reliance on donor recruit-
ment, and the risks of transfusion transmitted infection and of
immune incompatibility, through provision of a ‘universal donor’
blood group (such as O Rhesus D negative and Kell negative). Since
the product will consist of a homogeneous population of young
red cells (reticulocytes), the cells should have a longer life span
once transfused. This would be of benefit to beta-thalassemia
patients, who may require fewer transfusions and therefore expe-
rience less iron loading. These benefits would justify a price
premium for the initial product, perhaps enabling it to cover
the cost of meeting the technical and regulatory constraints
described here.
The ALSIS approach
The method we developed for this project, Analysis of Life Science
Innovation Systems (ALSIS) [2] uses a strategic mapping approach
to project future business models and product development path-
ways (defined as the full range of activities required to bring a
product from conception to end use, including design, produc-
tion, marketing, distribution and support to the final consumer).
These factors, broadly speaking under the control of the innovator,
are embedded within an innovation ecosystem that includes the
economic, regulatory, societal and political contexts that are
beyond the control of the innovator, with either positive or
negative impacts on the product business plan. For the Blood-
pharma project, critical decision points within the product devel-
opment pathway arose from the scientific and technological
challenges of differentiating sufficient quantities of RBCs from
stem cells meeting clinical grade GMP standards for different
stages of pre-clinical and clinical testing; and the implications
for product development and regulatory science of targeting the
niche Thalassaemia market. The main innovation ecosystem com-
ponents discussed in this paper are the regulatory system and the
challenge of meeting requirements related to the use of conven-
tional preclinical animal models and to the conduct of human
clinical trials.
The strategic maps in Figs 1–4 were developed using Banxia
Decision Explorer software (http://www.banxia.com/dexplore/)
and are based on discussions with case study participants during
interviews and workshops. They consist of a series of ‘concepts’,
short statements, each representing an action that leads, as shown
by the arrows on the map, either causally or temporally to the nextwww.elsevier.com/locate/nbt 181
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of the projected product development pathway or elements of the
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ergenerally from left to right, with parallel processes and feedback
loops demonstrating the non-linearity of the process. Figs 1–4 are
summary versions of the more detailed strategic maps developed
for the case study [2]. Figure 1 is an overall value chain, showing
the parallel regulatory and manufacturing paths for the product,
from the development of a working stem cell bank and the crea-
tion of enucleated RBCs through to the projected Thalassemia
patient market. Figs 2–4 expand on manufacture and scale-up
aspects of the product development pathway and preclinical
and clinical regulatory requirements.
Data collection
Data were gathered in 2010–2012 from five workshops (4–8 parti-
cipants in each), three interviews with senior people involved in
the Bloodpharma project, and one interview with a former regu-
lator. Key informants included those responsible for commercia-
lisation/financing, regulatory affairs, GMP and manufacturing,
and basic scientific research. Published data and ‘grey literature’
also informed our analysis. Workshops and some interviews were
recorded and transcribed to enable us to capture detailed qualita-
tive and quantitative information from which to construct the
strategic maps. Development and refining of these maps was an
on-going process throughout the project, informed by meetings
and discussions with the Bloodpharma team, and also with
external stakeholders through a series of meetings organised by
the lead partners in the REALISE project, the Scottish Stem Cell
Network.Research results
Scientific and technological challenges
Figure 1 illustrates the sequence of decisions related to the scien-
tific and technical challenges in developing the cultured product,
showing the critical points in the overall pathway at which
manufacturing and scale-up decisions would need to be finalised
and where such decisions would interact with the regulatory
system. The first concepts at the start of the critical path, obtaining
a starting cell line and developing a working cell bank bring up the
question of the expected starting material. Between 2010-12 the
project was using human embryonic stem cell (hESC) lines as the
starting material, but the long-term plan was to use induced
pluripotent stem cell (iPSC) lines. Factors favouring that choice
included: the requirement for open-source hESC banking in the
UK [32]; and the European Brustle patent decision, limiting the
patentability of hESC-derived products in Europe [33,34]. This is
an example of how policy and regulatory decisions can rapidly
transform product development strategies. In addition, a techno-
logical justification for switching in future to iPSC lines was that
the cultured blood should ideally be type O RhD-negative, and no
GMP-grade hESC lines of that blood type were available.
Following the logic of the pathway in Fig. 1, the developers
should, where possible (e.g. except where hESCs have been in-
volved), secure intellectual property on the cell lines and on com-
ponents of the production process. Developers also need to meet
clinical grade GMP requirements for cells and facilities. At the time
of the REALISE project, the Bloodpharma team was in the process ofwww.elsevier.com/locate/nbt 183
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erattempting to derive enucleated RBCs from the nucleated red blood
cells that had been created in the laboratory as illustrated in the
purple boxes on the left hand side of Fig. 1. The target product was
one that exhibited: definitive erythroid lineage cells (including
globin switching); normal oxygen carrying capacity; morphology
that resembles normal RBCs, a deformability profile that matches
the natural product; and output scale-up to approximately 10e16
fully matured cells by the time the project reached Stage 3 clinical
trials. These enucleated RBCs were expected to carry a reduced risk of
adverse immunogenic response.
Cell enucleation, cell maturation and globin switching (switch-
ing from foetal to adult haemoglobin) were always going to be the
most urgent technical and scientific challenges facing the Blood-
pharma team in the early stages of product development. Globin
switching is important because different haemoglobins (embryon-
ic, foetal and adult) have different oxygen dissociation curves,
which can impact on the efficacy of the final product. Beyond the
preclinical challenges, the product development map splits into
parallel regulatory and manufacturing pathways, as discussed in
more detail below.
Clinical grade GMP production and scale-up
The critical path in Fig. 2 follows manufacturing and scale-up
decisions, from preclinical and clinical testing through to distri-
bution/storage. The need to achieve very significant degrees of
scale-up to clinical GMP standard is a major challenge in develop-184 www.elsevier.com/locate/nbting allogeneic stem cell therapies [35], although some of the
uncertainties are being reduced over time [7]. As shown on the
left hand side of Fig. 2, the large scale production of enucleated
RBCs would require a reliable, cost-effective supply of reagents and
the cost of goods would need to decline significantly in future if
allogeneic therapies are to be viable.
The phased scale-up of production capability for preclinical and
clinical testing was a significant challenge for the eventual com-
mercial production of cultured RBCs as for any allogeneic product.
If economies of scale can be achieved, the product would eventu-
ally benefit from having a well-established, well-regulated route to
market via the blood transfusion service’s sophisticated supply
chain. However, even for the niche thalassemia market, the need
to achieve significant step changes in production technology was
considered a make-or-break issue.
Key choices on this part of the pathway were: the location of
production facilities; development of sufficient production capac-
ity to meet the requirements for preclinical testing and clinical
trials; technologies for scale-up; and cost of goods for media and
stem cell growth factors. There was continuing uncertainty
about the number of tests required at each regulatory stage and
hence the number of cells needed, creating inherent risks to the
project at four points on Fig. 2, related to these regulatory decision
points.
1. Scale-up for preclinical testing was estimated to require
approximately 10e11 or 10e12 cells (provided in small batches)
New Biotechnology Volume 32, Number 1  January 2015 RESEARCH PAPER
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erdepending on regulatory requirements, which could be
achieved using the current manufacturing process.
2. Optimised prototype scale-up for the expected phase 1/2
compressed clinical trial would require approximately 10e15
cells which would produce about 1000 units of blood. While
this is a total figure, the cells could not be manufactured in a
single batch because of the limited life span of the product. The
suggested approach was to manufacture monthly batches of
approximately 10e14 for these clinical trials. Data on
manufacturing and scale-up processes would need to be
included in the clinical trial application to the Medicines
and Health Care products Regulatory Agency (MHRA),
including the Investigational Medicinal Products Dossier
(IMPD). An MHRA manufacturer licence for investigational
medicinal products (MIA/IMP) would also be required. At this
stage, there was also a perceived opportunity to provide RBCs
for diagnostic reagent testing or blood screening, creating a
potential early revenue stream. The Bloodpharma team
expected to make the decision on whether to continue with
the GMP hESC line or switch to a GMP iPSC line in 2016, prior
to commencing the phase 1/2 clinical trial.
3. Scale up for phase 3 clinical trials would require approximately
10e16 RBCs (or 10e15/month). As in the previous stage, any
new data on manufacturing techniques would need to be
integrated into plans for future batch processing techniques.
However, if the manufacturing technique was changed
substantially the IMPD would need to be updated.
4. Considering the thalassemia market, there are approximately
1000 UK based thalassemia patients and they would use
approximately 50,000 units (5  10e16 RBCs) per year. In
Europe there are approximately 70,000 thalassemia patients,
requiring 10e18 per year or 10e17 per month. At this stage,
scale-up to 10e18 RBCs (approximately a million units) per
year would provide sufficient supply for thalassemia markets
and for subsequent clinical trials for alternative blood markets.
At this stage, as for the previous stages, it would also be
necessary to demonstrate equivalency of the scale-up process
and final product.
If at any of these stages the ability to scale-up to the required
number of cells became technologically unachievable or unviable
due to the cost of goods (relative to the price that can be charged
for the product), or the product failed to meet regulatory require-
ments, the product would be at risk of failure. Products such as
this, developed by organisations without the resources of a multi-
national company, have very little capacity to accommodate any
serious delay, creating a requirement for a viable exit strategy. This
is a problem for most stem cell therapies currently in development.
The technology required for these levels of scale-up was not
available at the time of the study but given sufficient time and
resource it was assumed that the required levels of scale up would
be technologically feasible.
During the cell differentiation process the rate of maturation
and proliferation of the cell population varies at different steps and
the manufacturing process requirements (media, cytokine, culture
density, metabolic turnover) also vary. The biggest step forward
was expected to come from being able to grow cells in the later
stages of differentiation at very high cell density, reducing the total
volume in those steps when the cell numbers are greatest. Thiswould be equivalent to the technological improvements that have
been made over the last 10 years for antibody and protein thera-
peutic production in Chinese Hamster Ovary (CHO) and similar
cell lines. However, success would be dependent on fully under-
standing the cell requirements and having the capacity to modify
or supplement conditions appropriately.
While the level of public sector investment was expected to be
sufficient to take the product up to the stage of phase 1/2 clinical
trials, a phase 3 trial and final market delivery, even for the
thalassemia market, was estimated to require tens of millions
GBP in commercial investment. Furthermore, serving the thalas-
semia market would have implications for storage and distribution
systems as the largest numbers of patients are outside of the UK.
Location of production and distribution facilities, and storage and
distribution strategies (blue and yellow concepts on the right hand
side of Fig. 2), would therefore have to be aligned with initial and
potential future markets (top part of Fig. 4: green and yellow
concepts).
Regulatory systems
As Fig. 1 showed, there are close interactions between the
manufacturing and scale-up path adopted and the regulatory
system to which the product will be subject. One of the main
issues raised by this case study was the appropriateness of a
regulatory system that is based on a conventional pharmaceutical
regulatory model. The key decision points along the regulatory
pathway for the cultured blood product were preclinical animal
testing and Phase 1/2 human clinical trials.
The competent authorities governing regenerative medicine
therapies in the UK are the MHRA and the Human Tissue Authori-
ty (HTA), in addition to the Human Fertilisation and Embryology
Authority for approval to work with hESCs. They are responsible
for applying the European Directives that provide the legal basis
and regulatory oversight for RM products.
1. The EU Tissues and Cells Directives (Directive 2004/23/EC and
two technical directives -2006/17/EC and 2006/86/EC), are
transposed into UK law through the Human Tissues (Quality
and Safety for Human Use) Act1, the HTA being the UK
competent authority. They deal with products derived from
tissues or cells intended for human application, such as stem
cells for haematopoietic reconstitution, covering standards for
quality, safety and procurement of cell lines and GMP.
Together, these Directives ensure potential risks in research
and development are managed effectively.
2. The Clinical Trials Directive (2001/20/EC) provides a legal
framework for good clinical practice and governance of clinical
trials in Europe, and therefore the protection of human
research subjects. The Good Clinical Practice 2005/28/EC
Directive further ensures that trials are conducted according to
best practice.
3. The Advanced Therapy Medicinal Products (ATMP) Regulation
(EC Regulation 1394/2007) provides a centralised approvalwww.elsevier.com/locate/nbt 185
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efficacy and post authorisation vigilance. It also includes
special incentives for SMEs. Advanced therapies are defined as
‘. . . innovative, regenerative therapies which combine aspects
of medicine, cell biology, science and engineering for the
purpose of regenerating, repairing or replacing damaged
tissues or cells’. The ATMP Regulation plays an important
role in managing risk and judging efficacy for novel therapies
such as stem cells and tissue-engineered products. Its ‘risk
based approach’ [36] aims to promote health protection,
facilitate innovation and provide a degree of legal certainty
whilst allowing for technical flexibility.
Key components of the regulatory system for product efficacy
and safety are:
a. A central marketing authorisation procedure for advanced
therapy products requiring marketing and/or manufacturing
authorisation, including autologous and allogeneic human
tissue engineered products (hTEPs). Any cells substantially
manipulated, modified or based on an ‘engineered process’ are
subject to the regulation, but unmodified cells used in
transplants or for homologous use (such as bone marrow
transplants, peripheral blood and cord blood HSC transplan-
tation) are excluded. The emphasis of the approval process is
on demonstration of quality, safety and efficacy of treatment,
so these cell-based therapies are essentially treated as medici-
nal, pharmaceutical products.
b. A Committee for Advanced Therapies (CAT) within the
European Medicines Agency (EMA) to develop criteria and
guidelines for product evaluation, drawing on Community-
wide expertise.
c. Technical and risk management requirements to ensure
quality, safety, efficacy, traceability and post-marketing
surveillance.
d. Incentives built into the procedures to support innovation in
small and medium sized enterprises (SMEs) through fast-track
assessment and free advice, given that opaque and lengthy
regulatory procedures, coupled with a lack of scientific
expertise in some authorities, were making it difficult for
SMEs to bring human tissue-engineered products to market.
This excludes non-commercial organisations such as the UK
National Health Service (NHS).
e. The Regulation distinguishes between hospital-based and
commercial research, and specifies different regulatory require-
ments for hospitals growing cells for autologous treatments on a
non-routine basis. In the UK, the ‘hospital-exemption’ permits
medical doctors or surgeons in hospitals to provide treatments
to patients that have not been approved for trial or full licensing.
This has not been implemented in a common way across Europe
and it would not apply to the cultured blood product.
This centralised procedure for advanced therapies aims to re-
duce the risks and uncertainties faced by developers of such
therapies, but it does impose high regulatory hurdles for safety,
efficacy, quality and post-marketing surveillance. However, as the
Bloodpharma product will initially be developed for Thalassemia
patients, it is likely to qualify as an Orphan indication, reducing
some of the regulatory costs. Nevertheless the centralised proce-
dure, and the spirit of the ATMP regulation, is based on a phar-
maceutical model of regulation and its approach to judging safety186 www.elsevier.com/locate/nbtand efficacy of ATMPs, particularly preclinical and clinical testing.
Handling living material, maintaining its integrity and freedom
from contamination and delivering it to patients requires different
facilities and skill sets from those of the pharmaceutical innova-
tion system and these challenges are being met initially by the
smaller companies or public and private health service providers
that are at the forefront of developing the technology, as in the
case of the Bloodpharma team.
The principal regulatory questions on safety and efficacy of
cultured RBCs are: the appropriateness of animal models for
preclinical testing, and probable future regulatory requirements
at this stage of development; and requirements for the design and
execution of clinical trials, first for a niche Thalassemia market and
then for other blood-related markets and/or general transfusion.
Preclinical regulatory requirements
The Bloodpharma team expected that both in vitro characterisa-
tion of the product and proof of low risk of tumourgenicity would
be required, but there were no good animal models of human RBC
transfusion. Therefore, the best option was considered to be to test
for tumorigenicity from any residual hESC in a NOD-SCID knock-
out mouse [37] and test for recovery and survival of red cells after
transfusion into a NOG mouse to demonstrate comparability with
donated red cells.
Figure 3 illustrates the future decision points from establishing
an animal model (for both proof of concept and safety) and testing
protocols, to preparing the clinical trial application form. The
Bloodpharma team would need to define the quality control assays
and establish general quality standards for the cultured blood
product, in line with conventional regulatory requirements for
preclinical R&D and the IMPD application (see left side of Fig. 1
and green concept statements around ‘‘in vitro data’’ at the top of
Fig. 3).
Uncertainty about the regulatory requirements for pre-clinical
testing had still not been resolved during our project, yet decisions
made then would have implications for future product develop-
ment and the ability to take the product into a phase 1 clinical
trial. Figure 3 illustrates the development stages for animal and
non-animal preclinical work and maps the available options and
associated uncertainties. In deciding the type of animal model and
test protocols for proof of concept and safety testing, a number of
options were available with various resource and cost implications.
Case study participants considered it unlikely that regulators
would demand prohibitively time consuming and expensive ani-
mal studies, for example, creating animal red blood cells from an
embryonic stem cell line or creating transgenic animals or chi-
meras (two yellow concepts at the bottom of Fig. 3), but an
immune-compromised animal model could be required to estab-
lish a safety profile for the product. However, use of a homologous
animal model would not test the same medicinal product as the
human stem cell-derived cultured blood and, even in the latter
case, a question remains as to whether the comparison would be
relevant to the safety and efficacy of the product in humans. This is
a key problem for regenerative medicine products that the regula-
tory system in Europe has not yet been able to fully resolve.
Discussing these issues, the European Committee for Advanced
Therapies, which provides technical advice on behalf of the Euro-
pean Medicines Agency (EMA), stated: ‘the only relevant species
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cytokines and micro-environment are considered–is the human
being itself.’[38; p. 197]. Nevertheless, the CAT has also argued
that there are safety related aspects of cell therapies that can only
be addressed in preclinical animal models, including evaluation of
bio-distribution by invasive techniques or testing tumorigenic
potential with batches of the product cultured beyond specifica-
tion [38; p. 197].
The Bloodpharma team engaged early with the regulators to
discuss options for preclinical testing and this may enable them to
avoid extensive and potentially inappropriate animal testing
requirements. As illustrated on the left hand side of Fig. 3, an
evidence-based case for alternatives to animal testing must be made
and the team needed to establish robust in vitro data and to present a
strong scientific justification for its relevance and use in the clinical
trial dossier (IMPD) that would eventually be submitted to the
MHRA/EMA. The MHRA and EMA assess each product on a case-
by-case basis, considering the balance between risk and benefit. The
need for, and type of, animal testing should be assessed for compa-
rability to the clinical situation and the science. As there are cur-
rently no good animal models for blood transfusion, the
Bloodpharma team would need to make a case for the animal
and in vitro preclinical work that can realistically be delivered, with
the caveat that their value will be limited. For animal data, murine
models of intravenous blood transfusion can be used to explore cell
recovery and survival, and testing of enucleated RBCs in a small
animal model was expected to be required for assessing risk of
tumorigenicity. In vitro data were expected to include cell numbers,
morphology, haemoglobin content, nucleated cell content, rheol-
ogy, oxygen dissociation and antigen expression. Animal testing
continues to be held as a fundamental preclinical standard and
developers of innovative products must consider early in the devel-
opment process what regulators are likely to find acceptable as an
appropriate animal study.
If the regulatory requirements for preclinical studies are limited
to safety studies in a small animal model, accompanied by in vitro
data, the preclinical work was expected to cost approximately
£250,000 and take 6–12 months to complete. However, if regula-
tors did insist on a large animal study, and more extensive testing
protocols for safety and efficacy (with the limitations outlined
above), the time and cost could escalate substantially and pose a
threat to the long term viability of the project, and certainly the
ability of the team to reach the stage of human clinical trials.
Indeed, members of the Bloodpharma team stated that there is no
precedent for a successful large animal model of human red cell
transfusion. Figure 3 illustrates the greater level of complexity,
uncertainty and potential costs around animal testing (the bottom
half of the map), as opposed to in vitro data (top portion of the
map). This raises the question whether there is scope to rethink the
role of animal studies in the preclinical requirements for some
regenerative medicine therapies, and to give much greater weight
to in vitro techniques, to provide innovators with a very clear and
unambiguous route to first clinical trials.
Clinical trials
The beta-thalassemia target market chosen for the Bloodpharma
project was considered likely to be amenable to Orphan Medicinal
Product regulation, with the attendant benefits of extendedmarket exclusivity, fee reductions and protocol assistance. As a
small market, the volume of product required to conduct first in
human studies in a few patients would also be much lower than if
the target market was general transfusion, when first clinical
studies would require a large number of healthy volunteers.
Figure 4 illustrates the key regulatory steps from preparing the
clinical trial application, through the completion of first in human
studies to phase 3 clinical trials and beyond to the clinic. It
includes some of the market related decisions and uncertainties
that may be relevant to late stage product development. Beyond
the preclinical work outlined in Fig. 3, case study participants
developed a regulatory plan to cover three elements: (i) obtain
from the CAT classification of the end-product as an ATMP, (ii)
prepare for a combined phase 1/2 Clinical Trial Application for the
MHRA (left hand side of Fig. 4), including the IMPD (data on
manufacturing, testing, stability; and animal, preclinical and
quality control testing), and (iii) agree traceability standards with
regulators, establish the required patient follow-up period and
specify subjects for the phase 1 trial.
For the beta-thalassemia market, the phase 1/2 compressed
clinical trial was expected to be conducted on patients rather than
healthy volunteers. However, this would be subject to approval
from regulators based on the preclinical data. The number of
patients required was expected to be relatively low (n50), with
less than 10 being involved in the first studies. This would enable
the trial to take place in the UK, which would be less costly than
organising overseas trials. This trial would look primarily at prod-
uct safety (identifying any adventitious agents present or abnor-
mal glycosylation) and also begin to collect data on efficacy to feed
into the design of the phase 3 trials. The phase 1/2 study is a make-
or-break step for the therapy. It highlights the importance of
getting clarification on the regulatory requirements as early in
development as possible, and planning a robust regulatory strategy
for full product development, as summarised in Fig. 4.
Phase 3 trials require demonstration of product superiority, or at
least equivalence of performance, compared to conventional donor
blood. For thalassemia patients, the team expected that the cultured
blood product would perform better than conventional donor
blood. The reason for this is that there will be greater consistency
in maturity of the RBCs and, perhaps more crucially, they will be
consistently younger and therefore predicated to have a longer life
span post-transfusion, so less may need to be transfused for the same
clinical benefit. Case study participants did not expect the clinical
trial regulatory route to a thalassemia market to raise any prohibitive
surprises. However, the potential need for additional data to gain
marketing authorisation for other blood markets such as general
transfusion generates greater uncertainty about the regulatory route
to market illustrated on the right side of Fig. 4.
The health economics and reimbursement models will ulti-
mately determine the viability of the option to expand into
different markets, and will shape both marketing and manufactur-
ing strategies. Beyond the phase 3 trial, Figs 1,4 are more specula-
tive and liable to change than in earlier stages of development,
where there is greater certainty around likely regulatory require-
ments. However, these uncertainties would only emerge after the
product has been shown to be safe and effective for thalassemia
patients and there would then be further options to attract invest-
ment to develop the product for additional markets. Furthermore,www.elsevier.com/locate/nbt 187
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product’s performance and safety from the phase 3 thalassemia
trials, when negotiating with regulators on the design and conduct
of further trials for additional markets.
Discussion and conclusions: broader lessons for
translation of regenerative medicine to the clinic
Two important general discussion points emerge from this case
study: (i) related to the innovative capacity of regenerative
medicine therapies; and (ii) related to the potential role of inter-
disciplinary social science methods in supporting innovation
processes.
The innovative capacity of regenerative medicine therapies
The Bloodpharma product is a disruptive innovation and a
standard-setting exemplar for the future of allogeneic regenera-
tive medicine therapies. It is highly innovative and has eventual
mass-market potential as a safe alternative to donated blood,
building on more immediate niche applications, for example in
thalassemia. This case study has demonstrated the technical
and regulatory challenges facing the cultured blood product
and their complex interactions, requiring an integrated ap-
proach to foresighting future development pathways from a
relatively small team of people lacking the resources that
would be found in a larger commercial company. Innovators
working in information and communications technologies of-
ten refer to the existence of a ‘first mover advantage’. In this case
there seems to be a strong ‘first mover disadvantage’ in that it
falls to the first mover to cope with the regulatory and funding
uncertainties at the same time as resolving the scientific and
technical problems that will emerge for any highly innovative
product.
The regulatory system that governs pharmaceutical products
and is now being extended to allogeneic RM therapies has a long
history of gradual build-up of measures designed to ensure safety
and efficacy of new medicines. The time and cost of meeting these
complex regulatory requirements has increased substantially in
recent decades [10,39,40] and now only large multinational firms
are able to deliver new products to large patient populations. For
this reason, for stem cell and other advanced therapies being
developed by publicly funded research groups or small companies,
regulatory agencies are beginning to recognise the need for new
governance structures and are embracing developments in regula-
tory science to support more cost-effective regulatory systems [41–
43]. However, there are continuing difficulties in identifying and
exploiting viable routes to market for allogeneic RM products. The
efforts of regulators to overcome the hurdles facing RM products
are reflected in the EMA setting up the Innovation Taskforce to
provide a forum for dialogue, and the MHRA establishing the
Innovation Office to help organisations developing innovative
products to navigate the regulatory system. However, most
attempts to revise regulatory processes are piecemeal and incre-
mental, and do not go far enough in establishing a new approach
for RM therapies. The House of Lords (HOL) Report [5] stated that
the regulatory system for regenerative medicine in the UK was
overly complex and at a European level there is disparity in
different regulatory bodies’ attitudes to the challenges and how
best to meet them. Some experts that submitted evidence to the188 www.elsevier.com/locate/nbtHOL report noted that the current system requires significant
improvement.
Although options are being identified for designing and con-
ducting robust safety and efficacy trials in humans for the cultured
blood product, the ‘gold standard’ double-blind and placebo
controlled clinical trials, developed with conventional drug ther-
apies in mind, continues to be the default regulatory requirement.
Any alternative, such as adaptive trials or unconventional proto-
cols for recruitment and testing, must be justified on a case-by-case
basis, adding to the uncertainty, time and cost of development.
Webster et al. [44] question whether standard clinical trials will be
appropriate for many regenerative medicine products, and we
consider there to be some scope for considering a more radical
change to the clinical trial system to facilitate innovation of
unconventional therapies, whilst at the same time ensuring the
highest levels of safety and efficacy.
There are currently no sufficiently robust solutions to the
problem of clinical translation for RM. A strategy that requires
investing public money in such risky initiatives is likely to experi-
ence difficulties when, as will inevitably happen, some projects
fail. This adds to the case for a new approach to regulation that
considers systemic interactions across the science/innovation
pathway and the potential dual role of regulation in both ensuring
safety and fostering beneficial innovation.
Perhaps the most important decision taken by any regulatory
body is the initial choice of regulatory precedent for an innova-
tive technology. There are good reasons to make such decisions
at an early stage in the development of a new technology,
not least because commercial funders will require clarity on
this question before making any significant investments.
However, the earlier such decisions are taken, the greater the
chance that serious implementation problems will arise and
regulatory systems generally lack the adaptive capacity needed
to avoid the waste of resources that occurs when development is
stopped for potentially effective, safe and economically viable
products.
Regulatory agencies, in collaboration with scientists, are
beginning to develop an understanding of the challenges
raised by RM and are interested in novel approaches to regula-
tion such as adaptive licensing and innovative clinical trial
design. Clinical considerations are touched upon in an EMA
reflection paper on stem cell-based medicinal products [45] and
a number of schemes are available in Europe to facilitate new
pathways to market, for example under a reduced submission
package.
1. Conditional Approval2: This procedure is applicable when there
is a complete pharmaceutical and pre-clinical data package
and an almost complete set of clinical data, if it is considered
reasonably likely that the remaining data will be collected in a
short timeframe. To qualify, a product must be intended for
treatment, prevention or diagnosis of a seriously debilitating
or life-threatening disease; have designated orphan status; or
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European Community or WHO recognised health threats.
Conditional approval is valid for one year on a renewable basis.
2. Exceptional Circumstances Licensing3: This is used when it is
assumed that comprehensive data can never be provided, for
example because the disease is too rare, the scientific
knowledge is too limited, or because of specific ethical
constraints in that it would be unethical to submit seriously
ill patients to extensive tests.
3. Accelerated Assessment4: This procedure is designed to meet the
legitimate expectations of patients and to take account of the
increasingly rapid progress of science and new therapies. It
applies to medicinal products of major interest from the point
of view of public health and therapeutic innovation. An
application for an accelerated assessment procedure must
justify that the medicinal product will be of major public
health interest. Based on the request, the justifications
presented, and the recommendations of the rapporteurs, the
Committee for Medicinal Products for Human Use (CHMP)
will formulate a decision. Such a decision will be taken without
prejudice to the CHMP opinion (positive or negative) on the
granting of a marketing authorisation.
These examples demonstrate that there is regulatory interest in
trying to explore novel options for assessing safety and getting
innovative therapies into the clinic, but again these are often
piecemeal and seen as the exception rather than the norm.
Considering the limitations of conventional animal models for
regenerative medicine testing, regulators may be willing to ex-
plore innovations in regulatory science that would enable good
quality in vitro data to play a greater role in early stage proof of
concept and safety. New approaches in practice and standards,
approved for different types of regenerative medicine therapies,
would enable such regulatory innovations to become the norm
rather than the exception and this could reduce uncertainty
and facilitate clinical translation. However, such change will
require regulators and policymakers to embrace alternative
approaches and normalise a regenerative medicine-specific
approach to regulation.
The Bloodpharma project has the potential to deliver a high-
value commercial product that pushes the boundaries of both
science and regulation, if the manufacturing/scale-up challenges
can be overcome and the regulatory path to a successful demon-
stration that the product is safe and effective in the niche thalas-
semia market can be met. Despite the complexity and uncertainty
associated with the development of the cultured blood product
and concerns about the viability of regulatory routes to market,
the successful completion of each milestone does cumulatively
increase the potential commercial viability of the product. For
example, the Bloodpharma team are succeeding in addressing
some of the technical questions that seemed so challenging at
the beginning of this project in 2010:3 Guideline on Procedures for the Granting of a Marketing Authorisation under
Exceptional Circumstances, pursuant to Article 14(8) of Regulation (EC) No 726/
2004 (EMEA/357981/2005).
4 Guideline on the Procedure for Accelerated Assessment, Pursuant to Article
14(9) of Regulation (EC) No 726/2004.This is one example of how RM products are very different
from conventional pharmaceuticals and many biologics as
manufacturing and scale-up capacity is directly shaped by regu-
latory decisions or, in many cases, uncertainty about appropriate
protocols. As Williams [7] points out, there is today a much
greater appreciation of the way in which business models, pro-
duction systems, and approaches to managing the regulatory
burden of manufacturing are closely intertwined. He notes that
regulators have a difficult task in balancing risk and therapeutic
benefit with the challenge of validating GMP manufacturing: ‘A
key part of determining a cost-effective manufacturing strategy
for a regenerative medicine product is to understand the inter-
play between alternative manufacturing solutions, business
models, their associated regulatory burden and risk in all its
dimensions.’ [7; p. 68]. The Bloodpharma team can be seen as
trying to design optimal manufacturing processes to clinical
grade GMP standards and to align them with this uncertain
and changing regulatory pathway. These factors render the
complexities, uncertainties and costs of R&D for such products
far more significant than for conventional therapies, with rela-
tively well known and understood manufacturing processes and
supply chains.
One suggestion for expediting translation of RM therapies to the
clinic, in the context of regulatory challenges, is to promote more
structured industry-academic collaboration and pre-competitive
cooperation [46]. However, valuable as such an approach might
be, a much more flexible and adaptive regulatory and governance
framework, beyond piecemeal attempts to streamline regulatory
processes and modify some regulatory science protocols, would
have the greatest and most positive impact on the clinical transla-
tion of RM.
In the case of the Bloodpharma project and similar types of
allogeneic therapy, we have identified innovative regulatory sci-
ence coupled with more flexible and bespoke regulatory
approaches as initiatives that could facilitate innovation whilst
maintaining the highest standards for safety and efficacy of the
therapy. This would be in the interests of companies developing
innovative therapies and of regulatory organisations. Products
such as cultured blood will continue to push the boundaries of
science, technology and regulatory regimes. This article has
mapped and described some of the critical points where the
science and manufacturing pathways could benefit from greater
flexibility in regulatory requirements.
The role of methodological innovation in supporting the
development of RM technologies
In parallel with the innovative character of the science and
technology contributing to the development of the cultured
blood product, the REALISE project [2] was the test bed for a
new approach to the analysis and foresighting of business models
and product development pathways for advanced innovative
technologies. The methodological innovation that underlies Figs
1–4 of this paper proved to be effective in analysing the complex
and uncertain innovation pathways for new RM products, help-
ing those developing the product to plan better in the face of
future scientific, regulatory and funding uncertainties. It is now
leading to the development of a framework of analytic methods
and guidelines to enable the analyst to shift focus from thewww.elsevier.com/locate/nbt 189
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to the regulatory and governance systems being developed by
policy makers, or to the agendas of stakeholders and third
sector actors.
Most of the evidence available to date on the factors that
support or inhibit innovation, across the board, comes from the
key actors in the process–the companies, regulators, or other
stakeholders, each of whom has a vested interest in a particular
set of outcomes and each therefore contributing their particular
biases to the case they make. It is particularly important to
have independent analyses, as described in this paper, in190 www.elsevier.com/locate/nbtsupport of better decision making by all involved in innovation
processes.
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